Please login to the form below

Not currently logged in
Email:
Password:

Merck KGaA 'to promote' Stefan Oschmann to chief executive

Germanphamra company reportedly set to elevate him to the top job next year

Merck KGaA Stefan OschmannMerck KGaA is set to elevate its deputy chief executive Stefan Oschmann to replace chief executive Karl-Ludwig Kley, according to local reports.

Manager Magazin says the German pharma company plans to promote Oschmann next year, either after its annual general meeting in May 2016 or when Kley's contract expires in September.

But a Merck spokeswoman told Reuters that a decision on Kley's succession had not yet been made and that this would be a matter for the family-controlled group's board of partners.

Oschmann has been vice chairman of Merck's executive board since January and prior to this was responsible for Merck's Pharma business as Member of the Executive Board from 2011 to 2014.

Before joining Germany's Merck he worked for its namesake Merck & Co as the US company's president of emerging markets for Merck Sharp & Dohme (MSD), as its operations are known outside the US.

Prior to joining MSD Oschmann worked for the International Atomic Energy Agency IAEA from 1985 to 1987 and for the German Animal Health Federation (BfT) from 1987 to 1989.

26th March 2015

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Infographics